Edwards Lifesciences Enters Definitive Deal To Sell Its Critical Care Product Group To BD In All-Cash Transaction Valued At $4.2B
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences has entered a definitive agreement to sell its Critical Care Product Group to BD for $4.2 billion in an all-cash transaction. The deal is expected to close by the end of 2024, subject to regulatory approvals. Edwards will use the proceeds for strategic growth investments.
June 03, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BD is acquiring Edwards Lifesciences' Critical Care Product Group for $4.2 billion. The transaction is expected to close by the end of 2024, subject to regulatory approvals.
The acquisition of Edwards Lifesciences' Critical Care Product Group is a significant investment for BD, potentially expanding its product portfolio and market reach. The deal is subject to regulatory approvals and is expected to close by the end of 2024.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Edwards Lifesciences is selling its Critical Care Product Group to BD for $4.2 billion. The proceeds will be used for strategic growth investments. The transaction is expected to close by the end of 2024, with minimal impact on 2024 EPS.
The sale will provide Edwards Lifesciences with significant cash proceeds, which will be used for strategic growth investments. This is likely to be viewed positively by investors, although the impact on 2024 EPS is expected to be minimal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100